

**IMMUNOVANT, INC.**  
**320 West 37th Street**  
**New York, NY 10018**

April 10, 2020

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: Immunovant, Inc.**  
**Registration Statement on Form S-1**  
**File No. 333-237627**

**Acceleration Request**

**Requested Date:**

**April 14, 2020**

**Requested Time:**

**9:00 a.m., Eastern Daylight Time**

Ladies and Gentlemen:

The undersigned Registrant hereby requests that the staff of the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced Registration Statement to become effective on April 14, 2020, at 9:00 a.m., Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of John McKenna and Alison Haggerty of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Alison Haggerty of Cooley LLP at (212) 479-6596.

Very truly yours,

**Immunovant, Inc.**

By: /s/ Peter Salzmann, M.D.

Name: Peter Salzmann, M.D.

Title: Chief Executive Officer

cc: Pamela Yanchik Connealy, *Immunovant, Inc.*  
W. Bradford Middlekauff, *Immunovant, Inc.*  
Frank F. Rahmani, *Cooley LLP*  
John T. McKenna, *Cooley LLP*  
Alison A. Haggerty, *Cooley LLP*